SUNHO BIO-B News

Shenghe Life Sciences-B (02898) released its interim performance, with a loss of 36.077 million yuan during the period, a year-on-year narrowing of 41.33%.

Shenghe Bio-B (02898) announced its interim performance for the six months ended June 30, 2024. During this period, the group...

Zhitong FinanceAug 30 06:44 ET

SUNHO BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEXAug 30 06:36 ET · Announcements

Shenghe Biotech-B (02898.HK) will hold a board of directors meeting on August 30th to approve the interim performance.

Shenghe Bio-B (02898.HK) announced that the company will hold a board of directors meeting on August 30, 2024 to approve the interim performance of the company and its subsidiaries for the six months ending June 30, 2024, as well as its publication.

Gelonghui FinanceAug 20 05:33 ET

SUNHO BIO-B: NOTICE OF BOARD MEETING

HKEXAug 20 05:17 ET · Announcements

Sunho Biologics' Unit Enters Subscription Letters

MT NewswiresJul 1 06:50 ET

Shenghe Biotech-B (02898) associated with the proposed subscription fund.

Shenghe Biotech-B (02898) issued an announcement on the Smart Finance app that on June 28, 2024, its indirect wholly-owned subsidiary Sunho HK (as a subscriber) entered into a subscription letter. Sunho HK agrees to subscribe to the funds (North Rock, Prudent Wealth, and Vanguard) according to the terms of the subscription letter. In order to improve fund efficiency and increase fund operating returns, the group will reasonably use its surplus cash to subscribe to these funds for financial management purposes to earn additional income without affecting normal operations.

Zhitong FinanceJun 28 10:42 ET

Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut

MT NewswiresMay 24 04:43 ET

Sunho Biologics Shares Rise 7% in Hong Kong Debut

MT NewswiresMay 23 22:04 ET

IPO Announcement | Shenghe Bio-B (02898) was subscribed 10.08 times in public sale and listed on May 24

The company sold 34.1518 million shares globally, with the Hong Kong public offering accounting for 10% and the international offering accounting for 90%. The final sale price was HK$13.5 per share, with a net raise of approximately HK$391.6 million from the global offering

Zhitong FinanceMay 23 10:21 ET

Sunho Biologics Files Prospectus for IPO

MT NewswiresMay 15 20:49 ET